Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data

Gratwohl, 2013, Hematopoietic stem cell transplantation activity in Europe, Curr Opin Hematol, 20, 485, 10.1097/MOH.0b013e328364f573

Passweg, 2015, Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants, Bone Marrow Transplant, 50, 476, 10.1038/bmt.2014.312

Passweg, 2013, Hematopoietic SCT in Europe: data and trends in 2011, Bone Marrow Transplant, 48, 1161, 10.1038/bmt.2013.51

Ljungman, 2010, Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009, Bone Marrow Transplant, 45, 219, 10.1038/bmt.2009.141

Giralt, 2009, Advances in stem cell transplantation: making it better and safer, Clin Lymphoma Myeloma, 9, S293, 10.3816/CLM.2009.s.026

Ditschkowski, 2006, Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients, Clin Transplant, 20, 127, 10.1111/j.1399-0012.2005.00453.x

Griffith, 2010, Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management, Blood, 116, 1197, 10.1182/blood-2010-03-276576

Bhatia, 2007, Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study, Blood, 110, 3784, 10.1182/blood-2007-03-082933

Tichelli, 2015, Survivorship after allogeneic transplantation-management recommendations for the primary care provider, Curr Hematol Malig Rep, 10, 35, 10.1007/s11899-014-0243-0

Abou-Mourad, 2010, Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens, Bone Marrow Transplant, 45, 295, 10.1038/bmt.2009.128

Tichelli, 2007, Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation, Blood, 110, 3463, 10.1182/blood-2006-10-054080

DeFilipp, 2016, Metabolic syndrome and cardiovascular disease after hematopoietic cell transplantation: screening and preventive practice recommendations from the CIBMTR and EBMT, Biol Blood Marrow Transplant, 22, 1493, 10.1016/j.bbmt.2016.05.007

Chow, 2011, Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation, Ann Intern Med, 155, 21, 10.7326/0003-4819-155-1-201107050-00004

Basavaraju, 2002, Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications, Med Phys, 29, 2391, 10.1118/1.1509442

Tichelli, 2008, Vascular endothelium as 'novel' target of graft-versus-host disease, Best Pract Res Clin Haematol, 21, 139, 10.1016/j.beha.2008.02.002

Baker, 2007, Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study, Blood, 109, 1765, 10.1182/blood-2006-05-022335

Majhail, 2009, High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation, Bone Marrow Transplant, 43, 49, 10.1038/bmt.2008.263

Armenian, 2012, Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease, Blood, 120, 4505, 10.1182/blood-2012-06-437178

Lee, 2009, Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 15, 416, 10.1016/j.bbmt.2008.12.502

Blaser, 2012, Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 18, 575, 10.1016/j.bbmt.2011.08.003

Kagoya, 2012, Hyperlipidemia after allogeneic stem cell transplantation: prevalence, risk factors, and impact on prognosis, Clin Transplant, 26, E168, 10.1111/j.1399-0012.2012.01628.x

Kasiske, 2004, Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative, Am J Transplant, 4, 13, 10.1111/j.1600-6135.2004.0355.x

Taylor, 2004, Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients, Ann Pharmacother, 38, 205, 10.1345/aph.1D388

Savani, 2011, How I treat late effects in adults after allogeneic stem cell transplantation, Blood, 117, 3002, 10.1182/blood-2010-10-263095

National Cholesterol Education Program Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), 2002, Treatment of High Blood Cholesterol in A. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143

Majhail, 2012, Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation, Rev Bras Hematol Hemoter, 34, 109, 10.5581/1516-8484.20120032

Marini, 2015, Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patients, Biol Blood Marrow Transplant, 21, 809, 10.1016/j.bbmt.2014.10.027

Blaes, 2016, Cardiovascular Complications of Hematopoietic Stem Cell Transplantation, Curr Treat Options Cardiovasc Med, 18, 25, 10.1007/s11936-016-0447-9

Fukuyama, 2008, Validation of the Friedewald Equation for Evaluation of Plasma LDL-Cholesterol, J Clin Biochem Nutr, 43, 1, 10.3164/jcbn.2008036

Newcombe, 1998, Interval estimation for the difference between independent proportions: comparison of eleven methods, Stat Med, 17, 873, 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I

Miller, 2002, Cardiovascular toxicities of immunosuppressive agents, Am J Transplant, 2, 807, 10.1034/j.1600-6143.2002.20902.x

Taegtmeyer, 2011, Effect of ABCB1 genotype on pre- and post-cardiac transplantation plasma lipid concentrations, J Cardiovasc Transl Res, 4, 304, 10.1007/s12265-011-9269-z

Perrea, 2008, Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function, Int Urol Nephrol, 40, 521, 10.1007/s11255-007-9266-y

Watt, 2011, Metabolic syndrome: is immunosuppression to blame?, Liver Transpl, 17 Suppl 3, S38, 10.1002/lt.22386

Battiwalla, 2017, Long-term survivorship after hematopoietic cell transplantation: roadmap for research and care, Biol Blood Marrow Transplant, 23, 184, 10.1016/j.bbmt.2016.11.004

PharmaWiki

Wiggins, 2016, Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association, Circulation, 134, e468, 10.1161/CIR.0000000000000456

Carpenter, 2012, Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study, Clin Transplant, 26, E438, 10.1111/j.1399-0012.2012.01676.x

Riella, 2012, Dyslipidemia and its therapeutic challenges in renal transplantation, Am J Transplant, 12, 1975, 10.1111/j.1600-6143.2012.04084.x

Holdaas, 2005, Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study, Am J Transplant, 5, 2929, 10.1111/j.1600-6143.2005.01105.x

Mohammadi, 2016, Clinical use of statins in hematopoietic stem cell transplantation: old drugs and new horizons, Int J Hematol Oncol Stem Cell Res, 10, 42

Rotta, 2010, Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation, Blood, 115, 1288, 10.1182/blood-2009-08-240358

Broady, 2008, Graft-versus-host disease: suppression by statins, Nat Med, 14, 1155, 10.1038/nm1108-1155

Goff, 2014, 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 63, 2935, 10.1016/j.jacc.2013.11.005

Armenian, 2017, National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: the Cardiovascular Disease and Associated Risk Factors Working Group Report, Biol Blood Marrow Transplant, 23, 201, 10.1016/j.bbmt.2016.08.019

Sidhu, 2012, Fasting time and lipid levels in a community-based population: a cross-sectional study, Arch Intern Med, 172, 1707, 10.1001/archinternmed.2012.3708

Khera, 2012, Fasting for lipid testing: is it worth the trouble?: comment on "fasting time and lipid levels in a community-based population", Arch Intern Med, 172, 1710, 10.1001/2013.jamainternmed.263